CRONOS GROUP INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.53 CAD | +2.62% |
|
+8.95% | +27.44% |
| Sales 2024 * | 137M 100M 8.03B | Sales 2025 * | 164M 120M 9.6B | Capitalization | 1.35B 986M 78.97B |
|---|---|---|---|---|---|
| Net income 2024 * | -17M -12.43M -995M | Net income 2025 * | -10M -7.31M -586M | EV / Sales 2024 * | 1.18 x |
| Net cash position 2024 * | 1.19B 868M 69.51B | Net cash position 2025 * | 1.19B 871M 69.74B | EV / Sales 2025 * | 0.96 x |
| P/E ratio 2024 * |
-57.5
x | P/E ratio 2025 * |
-51.4
x | Employees | 356 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cronos Group Inc.
More recommendations
More press releases
| 1 day | +2.62% | ||
| 1 week | +8.95% | ||
| Current month | -0.56% | ||
| 1 month | -2.49% | ||
| 3 months | +32.71% | ||
| 6 months | +47.70% | ||
| Current year | +27.44% |
1 week
2.98
3.62
1 month
2.984.01
Current year
2.564.01
1 year
2.154.01
3 years
2.1511.37
5 years
2.1523.79
10 years
0.1432.95
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 37 | 05/11/15 | |
James Holm
DFI | Director of Finance/CFO | 41 | 13/11/22 |
Arye Weigensberg
CTO | Chief Tech/Sci/R&D Officer | 41 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 48 | 24/06/21 | |
James D. Rudyk
BRD | Director/Board Member | 57 | 31/01/18 |
Jason Adler
BRD | Director/Board Member | 52 | 11/07/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 3.53 | +2.62% | 218,164 |
| 25/04/24 | 3.44 | +0.88% | 63,048 |
| 24/04/24 | 3.41 | +0.29% | 211,054 |
| 23/04/24 | 3.4 | +5.59% | 203,330 |
| 22/04/24 | 3.22 | -0.62% | 479,893 |
Delayed Quote Toronto S.E., April 26, 2024 at 09:00 pm
More quotes
Cronos Group Inc. is a Canada-based global cannabinoid company engaged in building intellectual property by advancing cannabis research, technology and product development. The Companyâs segments include United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Companyâs international brand portfolio includes Spinach, PEACE NATURALS, and Lord Jones. The Lord Jones are hemp-derived cannabidiol (CBD) brand. Its Lord Jones Hash Fusions is a line-up of premium ice water hash infused pre-rolls. Its PEACE NATURALS offers Peppermint CBD, a blend of CBD extract, quality medium-chain triglycerides (MCT) oil, and a hint of natural peppermint flavor.
Sector
Pharmaceuticals
Calendar
08/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
3.53
CAD
Average target price
3.567
CAD
Spread / Average Target
+1.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.44% | 985M | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| +0.09% | 1.65B | |
| -7.89% | 1.68B | |
| -12.97% | 1.53B | |
| +33.40% | 1.38B |
- Stock Market
- Equities
- CRON Stock
